<div id="readability-page-1"><div>Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing. CARGO insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for CARGO by imposing a significant penalty if CARGO accepts a competing bid. We are investigating the conduct of the CARGO board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA5MTQ2MjUxODhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA5MTQ2MjUxODhyMQ"/> Ademi &amp; Fruchter LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 View source version on businesswire.com: https://www.businesswire.com/news/home/20250914625188/en/</div></div>

CRGX

Ademi 律师事务所正在调查 CARGO Therapeutics, Inc.（纳斯达克代码：CRGX）在与 Concentra Biosciences 交易中可能存在的信托责任违规行为。股东将获得每股 4.379 美元及一个附带价值权。调查的重点是 CARGO 董事会是否在为股东的最佳利益行事，因为该交易限制了竞争报价，并为内部人士提供了显著的利益。感兴趣的各方可以联系该事务所以获取更多信息

股东警示：Ademi 公司正在持续调查 Cargo Therapeutics, Inc.是否为其公众股东争取到了公平的价格